Systemic Lupus Erythematosus and COVID-19
Purpose of Review To describe the current state of knowledge regarding COVID-19 in patients with systemic lupus erythematosus (SLE). We focus on (i) SARS-CoV-2 vaccination uptake, immunogenicity and safety, and (ii) outcomes of COVID-19 in patients with SLE and pertinent risk factors for adverse sequelae. Recent Findings Notwithstanding the potential concern of patients about possible post-vaccination side-effects, the safety of anti-SARS-CoV-2 vaccines in patients with SLE has been undisputedly confirmed in numerous studies. Humoral immunogenicity is generally attained in SLE, although affected by the use of background immunosuppressive drugs, especially rituximab. The latter has also clearly been implicated with adverse COVID-19 outcomes in SLE, including need for hospitalization, mechanical ventilation and death. Summary Although the wide adoption of vaccination has significantly improved COVID-19 outcomes, patients with SLE continue to pose challenges during the pandemic, mainly owing to administered immunosuppressive medications..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current rheumatology reports - 25(2023), 10 vom: 21. Juli, Seite 192-203 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pappa, Maria [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s11926-023-01110-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2145573984 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2145573984 | ||
| 003 | DE-627 | ||
| 005 | 20240118105442.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11926-023-01110-z |2 doi | |
| 035 | |a (DE-627)OLC2145573984 | ||
| 035 | |a (DE-He213)s11926-023-01110-z-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.83$jRheumatologie$jOrthopädie |2 bkl | ||
| 100 | 1 | |a Pappa, Maria |e verfasserin |0 (orcid)0000-0003-1296-0693 |4 aut | |
| 245 | 1 | 0 | |a Systemic Lupus Erythematosus and COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Purpose of Review To describe the current state of knowledge regarding COVID-19 in patients with systemic lupus erythematosus (SLE). We focus on (i) SARS-CoV-2 vaccination uptake, immunogenicity and safety, and (ii) outcomes of COVID-19 in patients with SLE and pertinent risk factors for adverse sequelae. Recent Findings Notwithstanding the potential concern of patients about possible post-vaccination side-effects, the safety of anti-SARS-CoV-2 vaccines in patients with SLE has been undisputedly confirmed in numerous studies. Humoral immunogenicity is generally attained in SLE, although affected by the use of background immunosuppressive drugs, especially rituximab. The latter has also clearly been implicated with adverse COVID-19 outcomes in SLE, including need for hospitalization, mechanical ventilation and death. Summary Although the wide adoption of vaccination has significantly improved COVID-19 outcomes, patients with SLE continue to pose challenges during the pandemic, mainly owing to administered immunosuppressive medications. | ||
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Vaccination | |
| 650 | 4 | |a Outcomes | |
| 700 | 1 | |a Panagiotopoulos, Alexandros |4 aut | |
| 700 | 1 | |a Thomas, Konstantinos |0 (orcid)0000-0002-7489-7776 |4 aut | |
| 700 | 1 | |a Fanouriakis, Antonis |0 (orcid)0000-0003-2696-031X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current rheumatology reports |d Springer US, 1999 |g 25(2023), 10 vom: 21. Juli, Seite 192-203 |w (DE-627)334292913 |w (DE-600)2057357-1 |w (DE-576)9334292911 |x 1523-3774 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:10 |g day:21 |g month:07 |g pages:192-203 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11926-023-01110-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.83$jRheumatologie$jOrthopädie |q VZ |0 106409425 |0 (DE-625)106409425 |
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 10 |b 21 |c 07 |h 192-203 | ||